Monte Rosa Therapeutics (GLUE) Cash from Financing Activities (2020 - 2026)

Monte Rosa Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $328.3 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 2345150.0% year-over-year to $328.3 million; the TTM figure through Mar 2026 stood at $358.7 million (up 263.54% YoY), while the FY2025 annual figure was $30.4 million, down 69.31% from the prior year.
• Cash from Financing Activities was $328.3 million for Q1 2026 at Monte Rosa Therapeutics, up from $29.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $328.3 million in Q1 2026 to a low of -$217000.0 in Q3 2022.
• Historically, Cash from Financing Activities has averaged $29.7 million across 5 years, with a median of $365000.0 in 2025.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities slumped 100.74% in 2022, then jumped 2345150.0% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $20.4 million in 2022, then rose by 23.19% to $25.2 million in 2023, then plunged by 97.58% to $608000.0 in 2024, then surged by 4772.37% to $29.6 million in 2025, then jumped by 1008.34% to $328.3 million in 2026.
• The last three Cash from Financing Activities figures came in at $328.3 million (Q1 2026), $29.6 million (Q4 2025), and $348000.0 (Q3 2025), per Business Quant data.